Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $30.5 million.

  • Ligand Pharmaceuticals' Total Current Liabilities rose 2328.03% to $30.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.5 million, marking a year-over-year increase of 2328.03%. This contributed to the annual value of $37.1 million for FY2024, which is 12114.17% up from last year.
  • Per Ligand Pharmaceuticals' latest filing, its Total Current Liabilities stood at $30.5 million for Q3 2025, which was up 2328.03% from $64.7 million recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Total Current Liabilities registered a high of $167.9 million during Q2 2022, and its lowest value of $15.7 million during Q3 2023.
  • Over the past 5 years, Ligand Pharmaceuticals' median Total Current Liabilities value was $41.7 million (recorded in 2021), while the average stood at $57.0 million.
  • Its Total Current Liabilities has fluctuated over the past 5 years, first surged by 36875.92% in 2021, then tumbled by 8837.11% in 2023.
  • Over the past 5 years, Ligand Pharmaceuticals' Total Current Liabilities (Quarter) stood at $41.7 million in 2021, then surged by 137.15% to $98.8 million in 2022, then crashed by 83.02% to $16.8 million in 2023, then skyrocketed by 121.14% to $37.1 million in 2024, then fell by 17.71% to $30.5 million in 2025.
  • Its last three reported values are $30.5 million in Q3 2025, $64.7 million for Q2 2025, and $58.7 million during Q1 2025.